

| Dosage | Package | Price per Dose | Price | |
|---|---|---|---|---|
| 50mg | 180 pills | A$3.21 | A$722.97 A$578.38 | |
| 50mg | 120 pills | A$3.57 | A$534.61 A$427.68 | |
| 50mg | 90 pills | A$3.77 | A$423.80 A$339.04 | |
| 50mg | 60 pills | A$4.03 | A$301.92 A$241.53 | |
| 50mg | 30 pills | A$4.43 | A$166.18 A$132.94 | |
| 50mg | 10 pills | A$5.32 | A$66.46 A$53.16 | |
| 100mg | 180 pills | A$4.72 | A$1,060.93 A$848.74 | |
| 100mg | 120 pills | A$4.76 | A$714.66 A$571.73 | |
| 100mg | 90 pills | A$5.01 | A$562.31 A$449.85 | |
| 100mg | 60 pills | A$5.94 | A$445.96 A$356.77 | |
| 100mg | 30 pills | A$6.21 | A$232.66 A$186.13 | |
| 100mg | 10 pills | A$7.09 | A$88.62 A$70.89 | |
| 150mg | 180 pills | A$3.04 | A$684.19 A$547.35 Best Price | |
| 150mg | 120 pills | A$3.37 | A$504.13 A$403.31 | |
| 150mg | 90 pills | A$3.75 | A$421.03 A$336.82 | |
| 150mg | 60 pills | A$4.17 | A$313.00 A$250.40 | |
| 150mg | 30 pills | A$4.65 | A$174.49 A$139.59 | |
| 150mg | 20 pills | A$6.25 | A$155.10 A$124.08 | |
| 150mg | 10 pills | A$6.67 | A$83.08 A$66.46 | |
| 200mg | 180 pills | A$6.03 | A$1,354.56 A$1,083.65 Popular | |
| 200mg | 120 pills | A$6.34 | A$950.12 A$760.10 | |
| 200mg | 90 pills | A$7.05 | A$792.23 A$633.78 | |
| 200mg | 60 pills | A$7.45 | A$559.54 A$447.63 | |
| 200mg | 30 pills | A$9.20 | A$346.24 A$276.99 | |
| 200mg | 10 pills | A$9.97 | A$124.63 A$99.70 |
Disclaimer: This information is intended for Australia and may require a prescription depending on local rules. It is not a substitute for professional medical advice.
Diflucan (fluconazole) is an azole antifungal agent used to treat a range of fungal infections by inhibiting fungal growth. The medication belongs to a class of drugs that disrupts the synthesis of ergosterol, an essential component of fungal cell membranes.
Candida species are among the most frequent causes of invasive fungal infections, and candidemia can complicate hospital care. Such infections may require systemic antifungal therapy when a diagnosis is confirmed or strongly suspected.
Diflucan is a systemic antifungal medication that is active against many Candida species and certain other yeasts. Its activity is generally highest against yeasts that inhabit the human body rather than moulds that grow in the environment.
In Australia, fluconazole formulations are typically available by prescription and are used in hospital settings as well as in the community under clinician supervision. Pharmacists can provide guidance on appropriate use and potential interactions.
The mechanism of action involves inhibition of fungal lanosterol 14-alpha-demethylase, an enzyme required for conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disruption leads to impaired membrane integrity and inhibited fungal growth. The effect is concentration-dependent for certain fungal species and time-dependent for others, which informs dosing decisions in clinical practice.
Limitations exist: some fungal species show reduced susceptibility to fluconazole, and certain moulds are outside the spectrum of activity. Long-term use can be associated with adverse effects in susceptible individuals, particularly concerning liver function and central nervous system symptoms in rare cases. Consequently, monitoring and risk assessment are recommended where prolonged therapy is anticipated.
Approved indications typically include treatment of candidiasis at multiple body sites and certain cryptococcal infections, with data driving use in diverse clinical scenarios. The aim is to eradicate pathogenic yeasts while minimising recurrence and resistance.
In clinical practice, Diflucan is employed for uncomplicated and complicated mucosal candidiasis, including oropharyngeal and esophageal infections, depending on severity and patient factors. It is also used for candidemia or disseminated candidiasis in certain contexts, when systemic antifungal coverage is required and no alternative agents are contraindicated.
Off-label or widely practised uses may include treatment of some dermatophyte infections and antifungal prophylaxis in select high-risk patient groups, though the evidence base varies by indication. Where used off-label, consultation with a clinician is essential to balance benefits and potential risks.
In a hospital setting, fluconazole may be chosen for its favorable oral bioavailability and convenient dosing in appropriate populations. In community practice, oral tablets or suspensions offer flexibility depending on patient age, swallowing ability, and comorbidities. Always follow prescriber instructions and pharmacist guidance for duration and monitoring.
The primary approved indications include treatment of uncomplicated vaginal candidiasis, oropharyngeal candidiasis, esophageal candidiasis, cryptococcal meningitis in combination with other agents, and candidemia in selected patients. The exact regimen depends on the site and severity of infection, patient tolerance, and underlying conditions.
For uncomplicated vaginal candidiasis, a single-dose regimen is commonly described in guidelines, though local practices may vary. Ongoing symptoms or atypical presentations warrant testing and clinician review. Seek advice if there is any doubt about suitability for a given infection.
For systemic infections such as candidemia, fluconazole is used when the isolated organism is susceptible and no contraindications exist. Dosing and duration are guided by clinical response, laboratory data, and patient characteristics. If improvement is not observed, escalation or alternative antifungal therapy may be considered.
Cryptococcal meningitis treatment commonly relies on a combination approach with other antifungals in the initial phase, followed by consolidation therapy. The role of fluconazole in this setting depends on regimen design and local practices. Consultation with infectious disease specialists is advised in such cases.
Off-label practice may involve treatment of certain dermatologic fungal infections, such as cutaneous candidiasis and some seborrheic dermatitis presentations, where appropriate. The evidence base should be reviewed, and risks weighed against expected benefit.
In some patients with persistent or recurrent mucosal candidiasis, clinicians may consider extended courses or maintenance strategies guided by response and tolerability. Surveillance for adverse effects is essential during longer courses.
Off-label use for fungal infections beyond Candida species is generally not standard; confirmation with a clinician is recommended before initiating such treatment. If uncertainty exists, check the official patient information leaflet or consult a pharmacist.
To support appropriate use, a simple table summarises how fluconazole compares with some related azole antifungals in common clinical scenarios.
| Drug | Common uses | Notes |
| Fluconazole (Diflucan) | Candidiasis, cryptococcal infections | Good oral bioavailability; limited activity against moulds such as Aspergillus |
| Itraconazole | Dermatophytosis, onychomycosis, some systemic mould infections | Higher tissue penetration but more drug interactions |
| Voriconazole | Invasive mould infections including Aspergillus | Broader spectrum; potential for visual disturbances and phototoxicity |
At a basic level, fluconazole blocks the production of ergosterol, a key component of fungal cell membranes. Without ergosterol, the membrane becomes unstable, and fungal growth is inhibited. This leads to reduced viability of susceptible fungal cells and eventual death in many infections.
From a pharmacological perspective, fluconazole inhibits a fungal cytochrome P450 enzyme, lanosterol 14-alpha-demethylase, disrupting the synthesis of ergosterol. The disruption alters membrane fluidity and permeability, impairing essential processes within the fungal cell. In susceptible organisms, this results in fungistatic activity—stopping growth—and in some circumstances may contribute to fungicidal effects, depending on drug concentration and organism species.
In simple terms, the medication makes the fungal cell membrane leaky and less able to function, which helps the immune system clear the infection. Because human cell membranes differ in their sterol composition and enzyme targets, fluconazole tends to have selective antifungal activity with tolerable safety in many patients when used correctly.
Clinically, the spectrum of activity is concentration-dependent for certain species and time-dependent for others, which can influence how rapidly symptoms improve. The choice of fluconazole versus another antifungal agent reflects the infecting organism, site of infection, patient factors (such as kidney function), and potential drug interactions. Check the official leaflet or consult a healthcare professional if uncertainty exists.
Fluconazole is readily absorbed from the gastrointestinal tract, with high oral bioavailability. The drug distributes widely in body tissues and fluids, including the central nervous system, when the meninges are involved or when blood-brain barrier penetration is needed.
Elimination occurs primarily through renal excretion, with urinary clearance representing a major route of elimination. In patients with normal kidney function, clearance is predictable, but dose adjustments may be necessary in renal impairment to prevent accumulation and adverse effects. The drug tends to have a relatively long half-life, which supports once-daily dosing for many indications.
Metabolic processing in the liver is limited relative to some other antifungals, but interactions with hepatic enzymes can still occur, especially in patients taking multiple medicines. Liver function tests may be recommended in prolonged therapy or when risk factors for hepatotoxicity exist. Always report unusual fatigue, dark urine, or jaundice promptly.
Because of its broad tissue distribution, fluconazole can reach sites of infection that are difficult to penetrate with other agents. However, activity must align with the susceptibility of the organism. If the clinical response is slower than expected, re-evaluation by the treating clinician is advised.
Diflucan is available as an oral tablet and, in some formulations, as an oral suspension. The route and formulation chosen depend on patient age, swallowing ability, and infection type. Patients should take the medication with water and as prescribed by a clinician. Food generally does not markedly affect absorption, but local guidance should be followed.
For uncomplicated vaginal candidiasis in many guidelines, a single-dose regimen is commonly described; however, local practice may differ. For other infections, more than one day of therapy or longer courses may be required, guided by site of infection and patient factors. The duration should be strictly as prescribed, and completion of the full course is important for effectiveness and resistance prevention.
Medication should be taken consistently at the same time each day when used for systemic infections or longer courses. If a dose is missed, the guidance provided by a clinician or pharmacist should be followed; do not double the next dose unless instructed. If there is doubt about timing, contact a healthcare professional for clarification.
Special situations, such as kidney impairment or pregnancy, may require adjustments to dosing or monitoring. In such cases, the prescriber will provide tailored recommendations. Do not modify the dose or discontinue therapy without professional advice.
Contraindications include known hypersensitivity to fluconazole or any azole antifungal, and significant liver disease where drug exposure could worsen outcomes. A history of severe liver disease or concurrent use of drugs with potential cross-reactivity should be discussed with a clinician or pharmacist prior to initiation.
Common adverse effects are typically mild and may include gastrointestinal upset, headache, or skin rashes. In rare cases, serious liver-related events or severe skin reactions may occur. Any unusual symptoms such as persistent nausea, yellowing of the skin or eyes, dark urine, or severe rash should prompt medical attention.
Drug interactions can be clinically important. Fluconazole can increase the levels of certain medicines by inhibiting their metabolism, including anticoagulants, some antidiabetic agents, and immunosuppressants. A comprehensive medication list should be reviewed with a pharmacist or clinician to assess interaction risk before starting therapy.
Renal impairment can necessitate dose adjustments because fluconazole is primarily eliminated by the kidneys. In patients with reduced kidney function, monitoring of drug levels and clinical response may be advised, and dose changes can be necessary to maintain safety and efficacy.
In pregnancy, the use of fluconazole should be carefully considered, weighing benefits against potential risks to the fetus. It may be avoided or limited to specific circumstances under professional supervision. Consultation with a clinician is essential when pregnancy is present or planned while a fluconazole course is contemplated.
Breastfeeding is a consideration, as fluconazole can be excreted into breast milk. If continued therapy is needed, the potential benefits and risks to the infant should be discussed with a healthcare professional to determine whether supplementation or alternate treatments might be appropriate.
In paediatric populations, dosing is carefully determined based on weight and infection type. Pediatric guidelines differ from adult recommendations, and specialist input may be required to ensure safe and effective use in children. Always follow the dosing instructions provided by the prescriber and pharmacist for young patients.
Geriatric use typically follows the same pharmacokinetic principles as younger adults, but the presence of comorbidities and polypharmacy increases the likelihood of interactions and adverse effects. Monitoring and dose considerations should reflect overall health status and concomitant medications.
Diflucan should be stored at room temperature, protected from moisture and light, and kept out of reach of children. Do not use the medication after the expiry date printed on the packaging. Check the packaging for any signs of damage before use.
Any tablets damaged or discoloured should not be used. The oral suspension should be prepared and stored according to the product instructions or pharmacy guidance, and any unused portions should be disposed of following local regulations. Do not flush medicines down the toilet unless instructed.
Pharmacists can provide information on proper storage and disposal if questions arise. If there is any concern about medicine safety or stability, contact a healthcare professional for advice before use.
Always keep medicines in their original packaging with the label intact to ensure the correct product and dosing information is available. Return any medicines that are no longer needed to a pharmacist for safe disposal where appropriate.
If a dose is missed, do not double the next dose unless explicitly advised by a clinician or pharmacist. The appropriate action depends on the dosing schedule and the infection being treated. When in doubt, contact a healthcare professional for guidance.
In the event of an overdose or suspected poisoning, seek urgent medical help or contact a poison information service for instructions. Do not rely on self-management in such situations. Medical staff will provide instructions based on the amount taken and the patient’s condition.
For individuals with kidney impairment or on other medications, the risk of adverse effects or drug interactions may differ during overdose scenarios. Immediate professional consultation is advised if an overdose is suspected or if there are any concerning symptoms.
Patients and caregivers should report any unusual symptoms promptly to a healthcare professional, especially if they persist or worsen after a missed dose or suspected overdose. Ongoing communication with healthcare providers supports safe and effective treatment outcomes.
Fluconazole can affect liver function in some individuals. If a liver condition is present, it is important to discuss this with a clinician before starting therapy. Liver monitoring may be recommended during longer courses. If jaundice, dark urine, or severe fatigue occurs, seek medical advice promptly.
Moderate alcohol use does not have a well-defined interaction with fluconazole for all infections, but alcohol consumption can worsen liver strain in susceptible individuals. It is reasonable to limit alcohol intake and discuss alcohol use with a clinician if liver disease is present or if multiple medications are being used.
If a dose is missed, follow the instructions provided by the prescriber or pharmacist. Do not double up doses unless advised. If several doses are missed or if the schedule becomes confusing, contact a healthcare professional for clarification.
Use during pregnancy should be guided by a clinician. The potential benefits and risks must be weighed carefully, as fluconazole carries considerations for fetal exposure. A healthcare professional will determine whether the benefits justify use and may propose alternative treatments in some cases.
Yes, fluconazole can interact with certain medicines by altering their breakdown in the body. A comprehensive medication list should be reviewed to assess interaction risk. Pharmacists can help determine whether any adjustments are needed before starting therapy.
Symptom relief varies by infection site and severity. Some patients notice improvement within a few days, while others may require a complete course to achieve full resolution. If symptoms persist beyond the expected time frame or worsen, contact a clinician for review.
Long-term or preventive use may be appropriate in certain high-risk patients under specialist supervision. The decision depends on the underlying risk factors, infection history, and potential for resistance. Regular follow-up is advised to reassess safety and effectiveness.
A rash can signal an adverse reaction to fluconazole. Minor rashes may not require stopping therapy, but any widespread or severe rash, blistering, or mucosal involvement warrants immediate medical assessment. In case of suspected anaphylaxis, seek urgent medical help.
Fluconazole is active against many Candida species and certain yeasts, but not all fungi respond to treatment. Infections caused by moulds or fluconazole-resistant organisms may require alternative antifungal agents. The decision depends on laboratory results and clinical judgement.
Renal impairment may require dose adjustments to prevent drug accumulation. Availability of oral forms and the need for monitoring should be discussed with a clinician or pharmacist. Close supervision ensures safe use in this population.
Pediatric use is possible with age- and weight-appropriate dosing. Dosing recommendations for children differ from adults, and a clinician should determine the correct regimen. Caregivers should monitor for adverse effects and communicate any concerns to healthcare professionals.
Before initiating therapy, assess for allergies to fluconazole or other azoles, liver disease history, kidney function, and current medications to evaluate potential interactions. A pharmacist or clinician can review concomitant medicines and provide safety recommendations.
Diflucan may require a prescription depending on local rules. Availability may vary by state or territory and by the form of the product. A pharmacist or clinician can confirm how to obtain the medication legally and safely in the current location.
Diflucan is a systemic antifungal taken by mouth, which treats infections that affect internal organs and the bloodstream. Topical antifungals are applied to the skin or mucous membranes and are generally used for localized infections. The choice depends on the site and severity of infection and should be guided by a clinician.
In many infections, completing the full prescribed course reduces the risk of relapse and resistance. If there is concern about tolerability or adverse effects, contact a clinician to determine whether continuation is appropriate. Do not alter the course without professional advice.
Food intake typically does not dramatically affect absorption for oral fluconazole. If a clinician has given specific instructions about taking with or without meals, those instructions should be followed. Otherwise, consistency in timing is useful for maintaining stable drug levels.
Monitoring may include liver function tests, kidney function in appropriate patients, and assessment of clinical response. Routine monitoring is more likely for prolonged therapy or when risk factors for adverse effects exist. Any new symptoms should prompt a consultation with a healthcare professional.
14–21 days. Free from A$285.95 .
5–9 days. A$42.89
−10% when paying with cryptocurrency.
−10% on all repeat orders.
All orders are packed in neutral, unbranded boxes with no product name on the outside.
